About Clovis Oncology
Clovis Oncology is a company based in Boulder (United States) founded in 2009. It operates as a B2B. Clovis Oncology has raised $423.26 million across 6 funding rounds from investors including State Street, Frazier Healthcare Partners and Abingworth. The company has 280 employees as of December 31, 2022. Clovis Oncology has completed 1 acquisition, including EOS Milano. Clovis Oncology operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Boulder, United States
- Employees 280 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Clovis Oncology, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$423.26 M (USD)
in 6 rounds
-
Latest Funding Round
$7.5 M (USD), Series C
Nov 24, 2020
-
Investors
State Street
& 7 more
-
Employee Count
280
as on Dec 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Clovis Oncology
Unlock access to complete
Funding Insights of Clovis Oncology
Clovis Oncology has successfully raised a total of $423.26M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $7.5 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series C — $7.5M
-
First Round
First Round
(01 Jun 2011)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2020 | Amount | Series C - Clovis Oncology | Valuation |
investors |
|
| Nov, 2020 | Amount | Series C - Clovis Oncology | Valuation |
investors |
|
| Jul, 2019 | Amount | Series C - Clovis Oncology | Valuation |
investors |
Investors in Clovis Oncology
Clovis Oncology has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include State Street, Frazier Healthcare Partners and Abingworth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life science & tech focused VC firm investing in the US
|
Founded Year | Domain | Location | |
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location | |
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Clovis Oncology
Clovis Oncology has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include EOS Milano.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of Lucitanib - an oral small molecule tyrosine kinase inhibitor to prevent tumor angiogenesis
|
2005 |
Financial Statements - Clovis Oncology
Clovis Oncology Comparisons
Competitors of Clovis Oncology
Clovis Oncology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
Frequently Asked Questions about Clovis Oncology
Clovis Oncology was founded in 2009 and raised its 1st funding round 2 years after it was founded.
Clovis Oncology is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
Clovis Oncology is a funded company, having raised a total of $423.26M across 6 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Clovis Oncology is 280.
Clovis Oncology, based in Boulder, focuses on providing healthcare solutions, advancing biotech innovations, oncology, and immunotherapy. Develops innovative immunotherapy drugs for cancer treatment. The company prioritizes operational excellence, innovation, and customer-centric approaches for success. It continues to evolve, meeting industry challenges with strategic approaches.
Clovis Oncology's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Clovis Oncology has made 1 acquisition, including EOS Milano.
Clovis Oncology has 8 investors. Key investors include State Street, Frazier Healthcare Partners, Abingworth, Domain Associates, and NEA.